[go: up one dir, main page]

PE20181893A1 - Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparacion y usos terapeuticos de los mismos - Google Patents

Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparacion y usos terapeuticos de los mismos

Info

Publication number
PE20181893A1
PE20181893A1 PE2018001528A PE2018001528A PE20181893A1 PE 20181893 A1 PE20181893 A1 PE 20181893A1 PE 2018001528 A PE2018001528 A PE 2018001528A PE 2018001528 A PE2018001528 A PE 2018001528A PE 20181893 A1 PE20181893 A1 PE 20181893A1
Authority
PE
Peru
Prior art keywords
compounds
hydrogen
benzo
dihydro
preparation
Prior art date
Application number
PE2018001528A
Other languages
English (en)
Inventor
Monsif Bouaboula
Maurice Brollo
Victor Certal
Youssef El-Ahmad
Bruno Filoche-Romme
Frank Halley
Gary Mccort
Laurent Schio
Michel Tabart
Corinne Terrier
Fabienne Thompson
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of PE20181893A1 publication Critical patent/PE20181893A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Referido a compuestos 6,7-dihidro-5H-benzo[7]anuleno sustituidos de formula (I), en donde: R1 y R2 son, independientemente, hidrogeno o deuterio, R3 es hidrogeno, -COOH, -OH o -OPO(OH)2; R4 es hidrogeno o fluor; R5 es hidrogeno o -OH; en donde: al menos uno de R3 o R5 es diferente de hidrogeno; cuando R3 es -COOH, -OH u -OPO(OH)2, entonces R5 es hidrogeno; cuando R5 es -OH, entonces R3 y R4 son, cada uno, hidrogeno y R6 se selecciona entre fenilo, heteroarilo, cicloalquilo o heterocicloalquilo opcionalmente sustituidos. Dichos compuestos son inhibidores y degradadores de los receptores de estrogeno. Tambien refiere a un proceso de preparacion y el uso estos compuestos en el tratamiento del cancer.
PE2018001528A 2016-02-15 2017-02-14 Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparacion y usos terapeuticos de los mismos PE20181893A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305174 2016-02-15

Publications (1)

Publication Number Publication Date
PE20181893A1 true PE20181893A1 (es) 2018-12-11

Family

ID=55398242

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001528A PE20181893A1 (es) 2016-02-15 2017-02-14 Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparacion y usos terapeuticos de los mismos

Country Status (37)

Country Link
US (7) US9714221B1 (es)
EP (2) EP3524600B1 (es)
JP (4) JP6425852B1 (es)
KR (2) KR102813742B1 (es)
CN (2) CN108884079B (es)
AR (1) AR107616A1 (es)
AU (2) AU2017221083B2 (es)
BR (1) BR112018016490A2 (es)
CA (1) CA3014424A1 (es)
CL (1) CL2018002290A1 (es)
CO (1) CO2018009534A2 (es)
CR (1) CR20180442A (es)
CY (1) CY1125165T1 (es)
DK (2) DK3524600T3 (es)
DO (1) DOP2018000184A (es)
EA (2) EA034994B1 (es)
EC (1) ECSP18069466A (es)
ES (2) ES2906208T3 (es)
HR (1) HRP20211043T1 (es)
HU (2) HUE055107T2 (es)
IL (2) IL261099B (es)
LT (1) LT3416962T (es)
MA (2) MA46479A (es)
MX (2) MX380091B (es)
MY (2) MY196486A (es)
PE (1) PE20181893A1 (es)
PH (1) PH12018501679A1 (es)
PL (1) PL3416962T3 (es)
PT (1) PT3416962T (es)
RS (1) RS62132B1 (es)
SG (2) SG10202106024XA (es)
SI (1) SI3416962T1 (es)
TN (1) TN2018000285A1 (es)
TW (3) TWI779621B (es)
UY (1) UY37124A (es)
WO (1) WO2017140669A1 (es)
ZA (1) ZA201805137B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102813742B1 (ko) * 2016-02-15 2025-05-28 사노피 에스트로겐 수용체 조절자로서의 6,7-디하이드로-5h-벤조[7]아눌렌 유도체
ES3039455T3 (en) * 2016-11-17 2025-10-21 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
KR102765922B1 (ko) 2018-02-06 2025-02-11 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
CN113490850B (zh) 2018-08-17 2024-12-06 基因泰克公司 用于治疗乳腺癌的诊断和治疗方法
CN112638869B (zh) * 2018-09-07 2025-04-25 赛诺菲 6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的盐及其制备方法
EP3699167A1 (en) 2019-02-22 2020-08-26 Sanofi Process for preparing methyl 1-benzosuberone-7-carboxylate
MX2021013711A (es) * 2019-05-09 2021-12-10 Sanofi Sa Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado.
KR102058384B1 (ko) * 2019-09-06 2019-12-24 강원대학교산학협력단 2h-벤조[7]에눌렌 화합물 및 이의 제조방법
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
US12528768B2 (en) 2019-12-09 2026-01-20 Sanofi Crystalline form of a 7H-benzo[7]annulene-2-carboxylic acid derivative
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
CN113896669B (zh) * 2020-06-22 2024-12-17 海南先声再明医药股份有限公司 雌激素受体调节剂及其用途
CN115916769B (zh) * 2020-06-28 2024-09-10 深圳扬厉医药技术有限公司 并环吲唑类化合物
TW202233572A (zh) 2020-10-19 2022-09-01 法商賽諾菲公司 新穎之經取代的6,7-二氫-5h-苯並[7]輪烯衍生物，其製備方法及其治療用途
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
CN116615414A (zh) * 2020-10-19 2023-08-18 赛诺菲 经取代的6,7-二氢-5h-苯并[7]轮烯化合物及其衍生物、其制备方法及其治疗用途
CN116782895A (zh) * 2020-11-23 2023-09-19 赛诺菲 包含阿贝西利和6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸的组合
EP4247977A2 (en) 2020-11-23 2023-09-27 Sanofi Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
EP4289841A4 (en) * 2021-02-04 2025-02-19 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
TW202304425A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含瑞博西尼和安森司群（ａｍｃｅｎｅｓｔｒａｎｔ）的組合
TW202304424A (zh) 2021-04-12 2023-02-01 法商賽諾菲公司 包含依維莫司和安森司群的組合
TW202313558A (zh) * 2021-07-08 2023-04-01 大陸商勤浩醫藥(蘇州)有限公司 一類苯并七元環類化合物及其應用
WO2023287938A1 (en) 2021-07-15 2023-01-19 Teva Pharmaceuticals International Gmbh Solid state forms of amcenestrant
WO2023125700A1 (zh) * 2021-12-28 2023-07-06 南京明德新药研发有限公司 四氢环庚吲唑化合物的盐型、晶型
TW202400136A (zh) 2022-03-13 2024-01-01 法商賽諾菲公司 以安森司群(amcenestrant)治療乳癌
WO2023187086A1 (en) 2022-03-31 2023-10-05 Sanofi Amorphous solid form of amcenestrant
JP2025512050A (ja) 2022-04-15 2025-04-16 サノフイ 新規の置換された４－アミノ－４－オキソ－ブト－２－エニル誘導体、それらの調製のためのプロセス及びその治療的使用
US20250248970A1 (en) 2022-04-15 2025-08-07 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof
US20250255848A1 (en) 2022-04-15 2025-08-14 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene derivatives, processes for their preparation and therapeutic uses thereof
US20250263390A1 (en) 2022-04-15 2025-08-21 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
JP2025513063A (ja) 2022-04-15 2025-04-22 サノフイ 新規置換フッ化ビニル－ｎ－プロピル－ピロリジン化合物、それを調製するためのプロセス及びその治療的使用
US20250262186A1 (en) 2022-04-15 2025-08-21 Sanofi Novel substituted fluorinated n-propyl-pyrrolidine and n-propyl-azetidine compounds, processes for their preparation and therapeutic uses thereof
WO2024006776A1 (en) * 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
CN119907798A (zh) 2022-08-25 2025-04-29 赛诺菲 新颖的取代的2,3,4,9-四氢-1h-吡啶并[3,4-b]吲哚甲酸衍生物、其制备方法及其治疗用途
JP2025531033A (ja) 2022-08-25 2025-09-19 サノフイ 新規の置換２－カルボニル－ベンゾチオフェン－６－カルボン酸誘導体、それらの調製のためのプロセス及びその治療的使用
CN119790048A (zh) 2022-08-25 2025-04-08 赛诺菲 新颖的取代的四氢异喹啉-6-甲酸衍生物、用于其制备的方法及其治疗用途
CN119744261A (zh) 2022-08-25 2025-04-01 赛诺菲 新颖的经取代的喹啉和四氢化萘甲酸衍生物及其治疗用途
CN119768396A (zh) 2022-08-25 2025-04-04 赛诺菲 新颖的取代的苯并噻吩-6-羧酸衍生物、其制备方法及其治疗用途
EP4584257A1 (en) 2022-09-09 2025-07-16 Sanofi Substituted tetrahydrocyclohepta[e]indole derivatives, processes for their preparation and therapeutic uses thereof
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
CN120615091A (zh) * 2023-01-16 2025-09-09 正大天晴药业集团股份有限公司 取代的苯并七元环化合物及其应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06506467A (ja) * 1991-03-08 1994-07-21 ローヌ−プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド 多環式三級アミンポリ芳香族スクアレンシンセターゼインヒビター
DE19833786A1 (de) 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
ATE286893T1 (de) 2001-01-24 2005-01-15 Chiesi Farma Spa 2h-1-benzopyran-derivative, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
EP1417169A2 (en) * 2001-08-11 2004-05-12 Bristol-Myers Squibb Pharma Company Selective estrogen receptor modulators
JP4554219B2 (ja) 2002-04-24 2010-09-29 メルク・シャープ・エンド・ドーム・コーポレイション エストロゲン受容体調節剤
EP1577288B1 (en) 2002-12-26 2014-07-23 Eisai R&D Management Co., Ltd. Selective estrogen receptor modulators
CA2824106A1 (en) * 2003-08-29 2005-03-10 Ono Pharmaceutical Co., Ltd. Compound capable of binding s1p receptor and pharmaceutical use thereof
MX2007000036A (es) * 2004-06-25 2007-05-18 Johnson & Johnson Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias.
US20050288238A1 (en) * 2004-06-28 2005-12-29 Pfizer Inc Benzocyclodecane derivatives with antitumor activity
DE102005014090A1 (de) * 2005-03-22 2006-09-28 Schering Ag 5H-Benzocycloheptenderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
JP5354775B2 (ja) * 2005-06-14 2013-11-27 ベイラー ユニバーシティ チューブリン結合活性を有するコンブレタスタチンアナログ
EP2048126A1 (de) * 2007-10-11 2009-04-15 Bayer Schering Pharma AG Benzocycloheptanderivate als selektiv wirksame Estrogene
EP2090579A1 (en) * 2008-01-29 2009-08-19 Sanofi-Aventis Substituted heteroarylamide diazepinopyrimidone derivatives
DE102010030538A1 (de) 2010-06-25 2011-12-29 Bayer Schering Pharma Aktiengesellschaft 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
US20120130129A1 (en) * 2010-11-16 2012-05-24 Baylor University Efficient Method for Preparing Functionalized Benzosuberenes
JP5886873B2 (ja) 2010-12-24 2016-03-16 メルク・シャープ・エンド・ドーム・ベー・フェー Ｎ置換アゼチジン誘導体
TW201329025A (zh) * 2011-11-01 2013-07-16 Astex Therapeutics Ltd 醫藥化合物
DE102011087987A1 (de) 2011-12-08 2013-06-13 Bayer Intellectual Property Gmbh 6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
CN102584687A (zh) 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
JP2015504049A (ja) * 2011-12-30 2015-02-05 センタウルス・バイオファーマ・カンパニー・リミテッドＣｅｎｔａｕｒｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 新規アリールアルケン誘導体およびその選択的エストロゲン受容体調整剤における使用
AP2015008673A0 (en) * 2013-02-19 2015-08-31 Bayer Pharma Aktiengesellchaft Bicyclo 2,3-benzodiazepines and spirocyclically substituted 2,3-benzodiazepines
WO2015028409A1 (de) * 2013-08-27 2015-03-05 Bayer Pharma Aktiengesellschaft 6,7-dihydro-5h-benzo[7]annulen-derivate, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN112375077A (zh) 2014-12-18 2021-02-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
SG10202104177VA (en) 2015-04-29 2021-05-28 Radius Pharmaceuticals Inc Methods of treating cancer
CN106924210A (zh) 2015-12-29 2017-07-07 北京新领先医药科技发展有限公司 一种含有帕布昔利布的胶囊剂及其制备方法
KR102813742B1 (ko) * 2016-02-15 2025-05-28 사노피 에스트로겐 수용체 조절자로서의 6,7-디하이드로-5h-벤조[7]아눌렌 유도체
ES3039455T3 (en) 2016-11-17 2025-10-21 Sanofi Sa Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof

Also Published As

Publication number Publication date
BR112018016490A2 (pt) 2018-12-18
DK3524600T3 (da) 2022-02-07
TWI779621B (zh) 2022-10-01
ES2906208T3 (es) 2022-04-13
SG10202106024XA (en) 2021-07-29
MY206566A (en) 2024-12-21
JP2019031537A (ja) 2019-02-28
IL277750B (en) 2022-06-01
UY37124A (es) 2017-09-29
LT3416962T (lt) 2021-07-12
EP3524600A1 (en) 2019-08-14
EP3524600B1 (en) 2021-11-17
CN112979524B (zh) 2024-09-10
PL3416962T3 (pl) 2021-11-22
CO2018009534A2 (es) 2018-09-20
EA201891841A1 (ru) 2019-01-31
AU2021225215B2 (en) 2023-05-25
US11214541B2 (en) 2022-01-04
KR20220098057A (ko) 2022-07-08
EP3416962A1 (en) 2018-12-26
JP6425852B1 (ja) 2018-11-21
SI3416962T1 (sl) 2021-08-31
CR20180442A (es) 2018-12-21
MY196486A (en) 2023-04-17
MA46479A (fr) 2019-08-14
TWI737681B (zh) 2021-09-01
US9714221B1 (en) 2017-07-25
TW202138349A (zh) 2021-10-16
CN108884079B (zh) 2021-03-05
EA034994B1 (ru) 2020-04-15
AU2017221083B2 (en) 2021-06-24
EP3416962B1 (en) 2021-05-05
US20180079720A1 (en) 2018-03-22
MX380091B (es) 2025-03-11
CL2018002290A1 (es) 2018-10-05
AU2021225215A1 (en) 2021-09-30
EA202090255A2 (ru) 2020-05-31
KR102813742B1 (ko) 2025-05-28
MA44226B1 (fr) 2021-07-29
IL277750A (en) 2020-11-30
KR20180105759A (ko) 2018-09-28
JP6695457B2 (ja) 2020-05-20
AU2017221083A1 (en) 2018-10-04
IL261099A (en) 2018-10-31
DK3416962T3 (da) 2021-07-26
CA3014424A1 (en) 2017-08-24
KR102813741B1 (ko) 2025-05-28
HUE055107T2 (hu) 2021-10-28
MX2020011469A (es) 2021-09-30
TW202138348A (zh) 2021-10-16
IL261099B (en) 2020-10-29
PT3416962T (pt) 2021-07-23
JP6476343B2 (ja) 2019-02-27
US10570090B2 (en) 2020-02-25
JP6868142B2 (ja) 2021-05-12
CY1125165T1 (el) 2023-06-09
TWI779620B (zh) 2022-10-01
MX2018009908A (es) 2018-09-07
ECSP18069466A (es) 2018-09-30
HRP20211043T1 (hr) 2021-10-01
JP2018537406A (ja) 2018-12-20
US20200392081A1 (en) 2020-12-17
AR107616A1 (es) 2018-05-16
PH12018501679A1 (en) 2019-06-10
TW201741285A (zh) 2017-12-01
JP2020128385A (ja) 2020-08-27
JP2019081776A (ja) 2019-05-30
ES2881508T3 (es) 2021-11-29
TN2018000285A1 (en) 2020-01-16
EA038639B1 (ru) 2021-09-28
MX386677B (es) 2025-03-19
ZA201805137B (en) 2023-09-27
CN112979524A (zh) 2021-06-18
US20170233340A1 (en) 2017-08-17
DOP2018000184A (es) 2019-01-31
WO2017140669A1 (en) 2017-08-24
RS62132B1 (sr) 2021-08-31
CN108884079A (zh) 2018-11-23
US20240150284A1 (en) 2024-05-09
US20210323916A1 (en) 2021-10-21
US20250368605A1 (en) 2025-12-04
US20220073460A1 (en) 2022-03-10
HUE057892T2 (hu) 2022-06-28
SG11201806829TA (en) 2018-09-27
EA202090255A3 (ru) 2020-07-31

Similar Documents

Publication Publication Date Title
PE20181893A1 (es) Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparacion y usos terapeuticos de los mismos
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
CO2017012786A2 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
DOP2017000304A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
DOP2017000195A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CL2017000240A1 (es) Compuestos activos hacia bromodominios
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MX2019005777A (es) Compuestos de n-(3fluoropropil)-pirrolidina sustituidos novedosos, procesos para su preparacion y usos terapeuticos de los mismos.
ECSP17002135A (es) Compuestos antiproliferativos y métodos de uso de los mismos
UY36734A (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2018000685A1 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CR20170590A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY32483A (es) Nuevos compuestos de bencimidazol para el tratamiento del virus sincicial respiratorio
BR112017024555A2 (pt) moduladores de ccr2
NI201400107A (es) Compuestos de heterociclilo como inhibidores de mek
CU20140143A7 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY35590A (es) Nuevos compuestos para el tratamiento del cáncer
CL2017000432A1 (es) Inhibidores espirocíclicos de catepsina c
ECSP17069696A (es) Compuestos novedosos
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CR20180181A (es) Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20180044A7 (es) Derivados novedosos de diamino piridina